New York State Common Retirement Fund Sells 2,000 Shares of United Therapeutics Co. (NASDAQ:UTHR)

New York State Common Retirement Fund lessened its position in shares of United Therapeutics Co. (NASDAQ:UTHR) by 5.4% in the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 34,815 shares of the biotechnology company’s stock after selling 2,000 shares during the period. New York State Common Retirement Fund owned approximately 0.08% of United Therapeutics worth $12,284,000 as of its most recent filing with the Securities and Exchange Commission.

Other large investors have also made changes to their positions in the company. Cardinal Capital Management lifted its stake in United Therapeutics by 1.9% during the fourth quarter. Cardinal Capital Management now owns 11,068 shares of the biotechnology company’s stock worth $3,905,000 after purchasing an additional 208 shares during the last quarter. Kestra Investment Management LLC bought a new stake in shares of United Therapeutics during the 4th quarter worth $603,000. Atria Wealth Solutions Inc. acquired a new stake in United Therapeutics in the fourth quarter valued at about $412,000. Venturi Wealth Management LLC bought a new position in United Therapeutics in the fourth quarter valued at about $136,000. Finally, CIBC Asset Management Inc raised its stake in United Therapeutics by 4.2% during the fourth quarter. CIBC Asset Management Inc now owns 1,598 shares of the biotechnology company’s stock worth $564,000 after acquiring an additional 65 shares in the last quarter. Institutional investors and hedge funds own 94.08% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities research analysts have recently weighed in on the stock. StockNews.com upgraded shares of United Therapeutics from a “buy” rating to a “strong-buy” rating in a research note on Thursday, January 16th. LADENBURG THALM/SH SH boosted their target price on shares of United Therapeutics from $319.00 to $344.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. UBS Group upped their price target on shares of United Therapeutics from $415.00 to $475.00 and gave the stock a “buy” rating in a report on Wednesday, January 8th. HC Wainwright raised their price objective on United Therapeutics from $400.00 to $425.00 and gave the company a “buy” rating in a report on Thursday, October 31st. Finally, Oppenheimer upped their target price on United Therapeutics from $575.00 to $600.00 and gave the stock an “outperform” rating in a report on Thursday, October 31st. One analyst has rated the stock with a sell rating, two have issued a hold rating, nine have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $388.25.

United Therapeutics Trading Down 0.8 %

Shares of UTHR stock opened at $358.21 on Tuesday. United Therapeutics Co. has a 1-year low of $221.53 and a 1-year high of $417.82. The stock has a market cap of $15.99 billion, a price-to-earnings ratio of 15.73, a PEG ratio of 0.97 and a beta of 0.57. The stock has a 50-day moving average of $362.39 and a 200-day moving average of $360.91.

Insider Buying and Selling at United Therapeutics

In other United Therapeutics news, EVP Paul A. Mahon sold 7,700 shares of the company’s stock in a transaction on Thursday, December 5th. The shares were sold at an average price of $374.37, for a total transaction of $2,882,649.00. Following the sale, the executive vice president now owns 36,710 shares of the company’s stock, valued at approximately $13,743,122.70. This represents a 17.34 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Michael Benkowitz sold 10,000 shares of United Therapeutics stock in a transaction dated Tuesday, February 18th. The stock was sold at an average price of $371.05, for a total value of $3,710,500.00. Following the completion of the transaction, the chief operating officer now directly owns 2,577 shares of the company’s stock, valued at approximately $956,195.85. This trade represents a 79.51 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders sold 114,164 shares of company stock valued at $41,671,293. 11.90% of the stock is currently owned by company insiders.

About United Therapeutics

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.